FV Hospital has cooperated with reputable international pharmaceutical companies to create the Free Partial Medicine Support Programme, also called “Patient Affordability Programme”, approved by the Ministry of Health in a few selected hospitals in Vietnam, including FV Hospital. Its aim is to reduce the financial burden for patients who can then have access to highly effective drugs for the duration of their treatment, improving treatment efficiency and quality of life.
The medicines supported under this programme are very expensive and are not covered by the Vietnamese Health Insurance. The eight drugs approved by the Ministry of Health for coverage under this programme are:
1. Tagrisso (Osimertinib): Indicated for patients diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for EGFR mutations or the EGFR T790M resistance mutation. It is also indicated as adjuvant therapy for adult patients with stage IB–IIIA NSCLC harboring epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R point mutations following complete tumor resection.
Form of assistance:
- During the first 6 months of treatment: After paying for 1 cycle of Tagrisso, the patient will be supported for 1 free cycle of Tagrisso (support level 1)
- From the 7th month to the 24th month of treatment: After paying for 1 cycle of Tagrisso, the patient is supported for 2 free cycles of Tagrisso (support level 2).
- From the 25th month of treatment onwards: After paying for 01 cycle of Tagrisso, the patient will be supported for 03 free cycles of Tagrisso (support level 3)
Program duration: From June 5, 2020, to December 31, 2029
2. Imfinzi (Durvalumab): is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC). For treated patients with a fixed dose 1500mg, after the patient buying/ 01 (one) box of Imfinzi 500 mg, they will receive 02 (two) boxes of Imfinzi 500 mg. For unresectable stage ill lung cancer patients receiving weight-based dose treatment: After they purchase and receive 01 (one) Imfinzi cycle*, they may receive another 01 (one) free Imfinzi cycle. Application period: is from April 6, 2022, to December 31, 2026.
3. Lynparza (Olaparib): Indicated for patients with ovarian cancer, breast cancer, varian cancer, adenocarcinoma of the pancreas and Prostate cancer. Patients buying/using 01 (one) Lynparza treatment cycle, they will receive 02 (two) Lynparza free treatment cycle. Application period: from April 6, 2022, to December 31, 2027.
4. PERJETA (Pertuzumab): Indicated for HER2-positive breast cancer patients. Patients who buy two bottles of Perjeta will receive one additional bottle, free of charge. Application period: from August 19, 2022, to December 31, 2025.
5. KEYTRUDA (Pembrolizumab): Indicated for the treatment of patients with the following cancers: (1) malignant melanoma; (2) non-small cell lung cancer (NSCLC); (3) classical Hodgkin lymphoma; (4) urothelial carcinoma; (5) head and neck cancer; (6) gastric cancer; (7) cancers exhibiting high microsatellite instability (MSI-H); (8) cervical cancer; (9) hepatocellular carcinoma (HCC); (10) MSI-H or mismatch repair-deficient colorectal cancer; (11) primary mediastinal large B-cell lymphoma; (12) esophageal cancer; (13) triple-negative breast cancer (TNBC); and (14) renal cell carcinoma
– Level 1:
Patients who self-pay 01 vial of KEYTRUDA (200 mg every 3 weeks) will get 01 free vial per treatment cycle. Adult patients who self-pay 02 vials (400 mg every 6 weeks) will get 02 free vials per treatment cycle.
– Level 2:
In the first 6 cycles, patients who self-pay 01 vial (200 mg every 3 weeks) will get 01 free vial per cycle; in the following 6 cycles, the medication is provided entirely free of charge. For adult patients on the 400 mg every 6 weeks regimen: in the first 6 cycles, those who self-pay 02 vials will get 02 free vials per cycle; in the next 6 cycles, the medication is fully covered.
– Level 3:
In the first 5 cycles, patients who self-pay 01 vial (200 mg every 3 weeks) will get 01 free vial per cycle; in the next 5 cycles, the treatment is completely free of charge. For adult patients receiving 400 mg every 6 weeks: in the first 5 cycles, those who self-pay 02 vials will get 02 free vials per cycle; in the next 5 cycles, the medication is fully sponsored.
Application period: from August 1, 2022, to December 31, 2026.
6. OFEV (Nintedanib): Indicated for the treatment of patients with idiopathic pulmonary fibrosis (IPF), other progressive fibrosing interstitial lung diseases (ILDs), and systemic sclerosis-associated interstitial lung disease (SSc-ILD). Patients who purchase 02 boxes of OFEV will receive 01 box free. Application period: From November 9, 2022, to December 31, 2025.
7. TECENTRIQ (atezolizumab): Indicated for treatment of Early-stage non-small cell lung cancer, Metastatic non-small cell lung cancer, Small cell lung cancer, Hepatocellular carcinoma and Metastatic urinary carcinoma. Patients pay their costs for 1 vial of TECENTRIQ (1200 mg) in the 1st, 3rd, and 4th cycles. Patients are supported free of charge with 1 vial of TECENTRIQ (content 1200 mg) in the 2nd and 5th cycles. Application period: is from 08/09/2023 until 31/12/2026.
8. Calquence (acalabrutinib): Indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). After using 01 CALQUENCE cycle out of pocket, patients will get 01 free CALQUENCE cycle. Application period: from November 27, 2024 to December 31, 2033.
Terms and conditions:
- The programme applies to all patients who are examined at FV and have a prescription from a doctor for one of the eight medicines described above.
- Patients must be provided with the terms and conditions and application period of the programme before making a decision.
- Patients must sign an agreement when participating in the programme.
- The programme applies until patient stops their treatment according to their doctor’s direction, or when they decide to stop participating in the programme, or when the programme expires.
Over the years, FV’s Hy Vong Cancer Centre, Ophthalmology & Refractive Surgery, Pulmonology and Internal Medicine departments have continuously developed and improved the quality of examination services. FV Hospital has also constantly updated and applied the world’s most advanced methods and techniques to help optimise treatment efficiency.
FV has a team of experienced, dedicated cancer, lung, and ophthalmology specialists who invest a great deal of time in understanding each case and caring for their patients. Each patient is consulted individually so that a personalised treatment regimen can be developed which depends on their condition, stage of disease, and medical history. FV’s international-standard treatment environment and modern facilities help patients to feel secure, think positively and stay hopeful that they will overcome their illness.
